The direct-to-consumer diagnostics company built its name on longevity biomarker panels. Now it’s betting its future on everything else.
Two years ago, Mito Health’s pitch was narrow and specific: order a panel of more than 100 biomarkers, skip the referral and get a longevity-minded readout on your own blood. That was the whole business. Recently, the San Francisco company said it has run more than one million lab tests and, in the process, has quietly become closer to a full preventive-health marketplace than a longevity-testing startup [1].
The company’s catalog has expanded to seven testing categories: standard lab panels, at-home kits, imaging and scans, whole genome sequencing, specialty kits and multi-cancer early detection, alongside the original biomarker work. Customers can walk into partner draw sites without insurance, without a referral and without the surprise billing that tends to follow lab work ordered the conventional way. At-home blood draws are now available in 35 states, and test kits ship to all 50.
From longevity niche to general front door
The shift says something about where the direct-to-consumer testing market is heading. Mito Health’s early customers were largely people already fluent in biomarker tracking, the sort who wanted VO2 max numbers and inflammatory markers alongside their annual physical. The company’s newer traffic looks different: people ordering fertility panels, tuberculosis tests required for school enrollment, baseline chronic disease screening or genetic risk testing, often because they’re between insurance plans or simply don’t want to wait weeks for a referral to clear.
“People rarely need just one kind of test,” said Rhonda Collins, FNP-C, who supports clinical operations at Mito Health. “Someone looking at fertility, or at family history, often needs bloodwork and imaging and sometimes genetics. Having those in one place means fewer places to get lost.”
The catalog now runs to more than 1,000 individual tests and panels, from single-marker orders up to the company’s 180-plus biomarker panel. Imaging has been added, too: DEXA body composition scans and whole-body MRI are both live, with coronary artery calcium scoring and VO2 max testing scheduled to follow.
Whole genome sequencing is offered at both 3x and 30x coverage, a distinction that roughly maps to how thoroughly the genome gets read, with the deeper option generally used when more precision is needed. Specialty kits cover gut microbiome analysis and H. pylori breath testing, and the company has added liquid biopsy testing aimed at multi-cancer early detection.
What hasn’t changed is the pricing model, and the company is leaning into it as much as the new categories. Everything in the catalog is sold at cost, supported by a flat $9-per-month membership rather than markups tied to individual tests.
“We wanted transparent preventive health prices, at cost, with one health membership,” said Kenneth Lou, co-founder and chief executive of Mito Health. “We earn the same whether someone buys a lot, a little or nothing at all. That is what lets us tell a customer the most useful thing is often to test less, not more.”
That’s a fairly unusual thing for a diagnostics company to say out loud, given that most of the industry’s revenue logic runs the other way: more tests ordered, more panels upsold. Mito Health’s flat-fee structure removes that incentive on paper, though it will be worth watching whether test volume actually settles into “less, not more” as the catalog grows, or whether a bigger menu simply gives more reasons to order.
Why the expansion still tracks back to longevity
It would be easy to read this as Mito Health drifting away from its original longevity focus into general-purpose diagnostics. The more accurate read is probably the opposite: the company’s expansion follows the logic of longevity medicine rather than departing from it. Fertility planning, chronic-disease baselines, inherited-risk screening, and cancer detection aren’t separate from healthspan tracking’ they’re the upstream inputs to it.
A 100-plus biomarker panel tells you a lot about where a body stands today, but the categories Mito Health has added – genetic risk, imaging, early cancer detection – are the pieces that let someone act on that picture years before a problem would otherwise surface. The company’s original customers wanted a longevity dashboard. What they’re getting now is the infrastructure underneath one.
[1] https://mitohealth.com/blog/mito-health-one-million-lab-tests
